Recent Updates
Recently added Catalysts
INSM

Insmed To Present at Two September Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
Price reaction · baseline $24.55 (2022-09-02 close) · hit after-hours · 1 other INSM headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Each webcast will be archived for a period of 30 days following the respective presentation dates.
About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater , New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Last updated: Sep 6, 2022